SCHEMBL873244

SCHEMBL873244

Cc1ccc(C[C@@H]2NC(=O)CN(Cc3ccccc3)C2=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.68
HDAC1 Q13547 4/20 0.68
HDAC8 Q9BY41 4/20 0.68
OPRK1 P41145 5/20 0.62
ALDH1A1 P00352 1/20 0.52
POLB P06746 2/20 0.48
GAA P10253 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.46
TACR1 P25103 1/20 0.44
PLA2G10 O15496 1/20 0.44
PLA2G5 P39877 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873243 1.00 HDAC6 (0.68) HDAC6HDAC1HDAC8OPRK1ALDH1A1
SCHEMBL8452072 0.92 HDAC6 (0.73) HDAC6HDAC1HDAC8OPRK1POLB
SCHEMBL877776 0.92 HDAC6 (0.73) HDAC6HDAC1HDAC8OPRK1POLB
SCHEMBL876552 0.92 HDAC6 (0.73) HDAC6HDAC1HDAC8OPRK1POLB
SCHEMBL5365461 0.88 HDAC6 (0.69) HDAC6HDAC1HDAC8OPRK1ALDH1A1
SCHEMBL877786 0.88 HDAC6 (0.69) HDAC6HDAC1HDAC8OPRK1POLB
SCHEMBL4289428 0.88 HDAC6 (0.69) HDAC6HDAC1HDAC8OPRK1POLB
SCHEMBL16457753 0.88 HDAC6 (0.69) HDAC6HDAC1HDAC8OPRK1POLB
SCHEMBL2084503 0.88 OPRK1 (0.63) HDAC6HDAC1HDAC8OPRK1ALDH1A1
SCHEMBL3494772 0.87 HDAC6 (0.71) HDAC6HDAC1HDAC8OPRK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
EP-1989188-B1 THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2015-07-22 EP disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
EP-2562168-B1 THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2014-04-16 EP disclosed
US-20140038945-A1 PIPERAZINE PDE4 INHIBITORS AND USES THEREOF DART NEUROSCIENCE (CAYMAN) LTD (KY) 2014-02-06 US disclosed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP disclosed
US-8501745-B2 Piperazine PDE4 inhibitors and uses thereof DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2013-08-06 US disclosed
EP-2562168-A1 Therapeutic piperazines as PDE4 inhibitors Helicon Therapeutics, Inc. (US) 2013-02-27 EP disclosed
US-8338405-B2 Therapeutic piperazines DART NEUROSCIENCE LLC (US) 2012-12-25 US disclosed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed
US-20110065688-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE LLC 2011-03-17 US disclosed
US-20110065689-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed
US-7829713-B2 Therapeutic piperazines HELICON THERAPEUTICS, INC. (US) 2010-11-09 US disclosed
US-20070203124-A1 Therapeutic Piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087645-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D HDAC6 291/4885HDAC1 224/4885HDAC8 913/4885
US-20070203124-A1 Therapeutic Piperazines PDE4A, PDE4B, PDE12 HDAC6 203/4885HDAC1 104/4885HDAC8 498/4885
US-20110065688-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE12 HDAC6 203/4885HDAC1 104/4885HDAC8 498/4885
US-20110065689-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE12 HDAC6 203/4885HDAC1 104/4885HDAC8 498/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D HDAC6 291/4885HDAC1 224/4885HDAC8 913/4885
US-20140038945-A1 PIPERAZINE PDE4 INHIBITORS AND USES THEREOF PDE4A, PDE12, PDE4B HDAC6 489/4885HDAC1 239/4885HDAC8 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.